Federated Hermes Inc. Has $2.62 Million Stake in OptimizeRx Co. (NASDAQ:OPRX)

Federated Hermes Inc. lessened its holdings in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 47.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 182,985 shares of the company's stock after selling 164,343 shares during the quarter. Federated Hermes Inc. owned approximately 1.01% of OptimizeRx worth $2,619,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of OPRX. Nisa Investment Advisors LLC lifted its holdings in shares of OptimizeRx by 215.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company's stock valued at $31,000 after buying an additional 1,462 shares during the last quarter. Quantbot Technologies LP acquired a new stake in OptimizeRx in the 3rd quarter worth approximately $49,000. L2 Asset Management LLC acquired a new stake in OptimizeRx in the 3rd quarter worth approximately $95,000. Jump Financial LLC acquired a new stake in OptimizeRx in the 3rd quarter worth approximately $101,000. Finally, Quadrature Capital Ltd acquired a new stake in OptimizeRx in the 3rd quarter worth approximately $162,000. Hedge funds and other institutional investors own 76.47% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on OPRX shares. JMP Securities restated a "market outperform" rating and issued a $15.00 target price on shares of OptimizeRx in a report on Tuesday, April 16th. Barclays initiated coverage on OptimizeRx in a research report on Wednesday, January 3rd. They issued an "equal weight" rating and a $15.00 price target on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $17.00 price target on shares of OptimizeRx in a research report on Monday, April 1st. Finally, Stifel Nicolaus reaffirmed a "buy" rating and issued a $13.00 price target on shares of OptimizeRx in a research report on Monday, April 1st. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $15.86.

OptimizeRx Price Performance

NASDAQ:OPRX traded up $1.32 during trading hours on Friday, reaching $10.12. The company had a trading volume of 489,074 shares, compared to its average volume of 123,107. The stock has a 50-day moving average of $12.61 and a two-hundred day moving average of $12.10. OptimizeRx Co. has a one year low of $6.92 and a one year high of $16.65. The firm has a market capitalization of $183.98 million, a PE ratio of -10.02 and a beta of 0.98. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.27.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $0.11 earnings per share for the quarter. OptimizeRx had a negative return on equity of 7.72% and a negative net margin of 24.56%. The firm had revenue of $28.37 million for the quarter. Analysts forecast that OptimizeRx Co. will post -0.49 earnings per share for the current year.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.